Wells Fargo analyst Derek Archila has maintained their bullish stance on KYMR stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Derek Archila has given his Buy rating due to a combination of factors influencing Kymera Therapeutics. Despite Sanofi’s decision to shift focus from KT-474 to KT-485, Archila views this as a minor setback in terms of timeline rather than a significant risk, as Kymera still benefits economically from the program. The core of his optimistic outlook remains centered on KT-621, which is seen as the primary driver of value for the company’s shares.
Additionally, the collaboration with Gilead on the CDK2 degrader adds further validation to Kymera’s platform, offering potential financial benefits through milestone payments and royalties. While the stock experienced a slight decline following the news, Archila believes the fundamental thesis around KT-621 remains strong, anticipating positive movements in the stock as more data becomes available. The strategic partnerships and the continued commitment from Sanofi reinforce confidence in Kymera’s future prospects.
In another report released yesterday, Jefferies also maintained a Buy rating on the stock with a $64.00 price target.